Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein that plays a critical role in cell growth and differentiation. Dysregulation and mutations in EGFR are implicated in various cancers, making it a prominent target for cancer therapy. Drug discovery efforts focus on developing inhibitors that can block EGFR signaling pathways, thereby preventing tumor growth and progression. Understanding the molecular mechanisms of EGFR and its role in oncogenesis is essential for designing effective therapeutic agents and improving cancer treatment outcomes.

1. Protein Purification

ICE Bioscience has successfully purified multiple proteins for EGFR family. Our protein team has years of rich experience, ensuring each batch undergoes activity verification to guarantee purity and activity, fully meeting various assay needs. 

2. Over 30 EGFR and Mutant Ready-to-Use Biochemical Assays

We offer a comprehensive range of biochemical assays for over 30 EGFR and its mutants.

3. SPR 

Surface Plasmon Resonance (SPR) is widely used in EGFR drug discovery to analyze the binding interactions between potential therapeutic compounds and the EGFR protein. SPR provides real-time, label-free detection of these interactions, allowing researchers to determine the affinity, kinetics, and specificity of drug candidates. This technology helps in identifying and optimizing lead compounds with high binding efficacy to EGFR, accelerating the development of effective EGFR-targeted therapies. 

4. EGFR Cell Line Screening

ICE Bioscience has established a platform of over 1000 cell lines, including overexpression and stable cell lines based on Flip-In, Lentiviral and Retroviral systems, Neon electroporation, T-REx system, HiBiT, and PPI systems, as well as gene-edited cell lines established using CRISPR/Cas 9, siRNA, and shRNA. For the EGFR target, ICE Bioscience has acquired 30 EGFR mutant-related Ba/F3 stable kinase cell lines, fully meeting various needs. We have a professional and efficient Ba/F3 technical team that can provide Ba/F3 cell line construction services to meet your specific cell line requirements. 

5. In Vivo Models 

As a critical step in the discovery of anti-tumor drugs, cell line-derived xenograft (CDX) models are widely used for preclinical testing of drug efficacy, PK/PD correlations, and combination therapies. These models make it feasible to study the efficacy and mechanisms of new drugs in inhibiting tumor growth and development.

FGFR (Fibroblast Growth Factor Receptor) is a critical target in drug discovery due to its role in cell growth, differentiation, and survival. Aberrations in FGFR signaling are associated with various cancers and developmental disorders. Drug discovery efforts focus on identifying inhibitors that can modulate FGFR activity, thereby providing therapeutic benefits in diseases driven by FGFR dysregulation. The development of FGFR-targeted therapies aims to selectively inhibit abnormal FGFR signaling pathways, offering potential treatments for patients with FGFR-related conditions. 

We offer an extensive range of over 30 FGFR proteins, including various mutants, available for purchase. These products are designed to facilitate advanced research and drug discovery efforts targeting FGFR pathways. 

We also provide robust enzyme activity assays utilizing cutting-edge ADP-Glo and HTRF (Homogeneous Time-Resolved Fluorescence) platforms. These technologies enable precise and sensitive measurement of kinase activity, offering researchers reliable tools to study FGFR function and inhibition in detail, ultimately aiding in the development of targeted therapies.

Lipid kinases, such as PI3K (Phosphoinositide 3-kinase), play crucial roles in cellular processes like growth, survival, and metabolism by phosphorylating lipids in cell membranes. Dysregulation of lipid kinase signaling pathways is implicated in various diseases, including cancer, diabetes, and cardiovascular disorders. Drug discovery efforts targeting lipid kinases aim to develop inhibitors that can modulate these pathways, offering potential therapeutic benefits. Understanding the molecular mechanisms and regulatory functions of lipid kinases is essential for designing effective inhibitors and advancing treatments for lipid kinase-associated diseases.

Cyclin-dependent kinases (CDKs) are critical regulators of the cell cycle and transcription. Dysregulation of CDK activity is associated with various cancers and proliferative disorders, making CDKs significant targets for drug discovery. Efforts in CDK drug discovery focus on developing selective inhibitors that can effectively block CDK activity, thereby halting uncontrolled cell division and tumor growth. Advances in understanding CDK structure, function, and regulatory mechanisms are essential for designing potent and specific CDK inhibitors, which have shown promise in improving cancer treatment outcomes.

ICE Bioscience's Biochemistry Division has expressed and purified over 20 high-purity, high-activity proteins from the CDK family. Our CDK kinase screening service utilizes the ADP-Glo assay, which quantitatively measures the production of ADP in reactions. This approach reflects the inhibition of kinase targets by compounds.